 reflux esophag therapi sucralf versu ranitidin doubl blind multicent trial sucralf Sc suspens g/day ranitidin Rn tablet mg patient double-blind multicent trial treatment reflux esophag inclus criteria symptomat reflux number sever attack endoscop evid esophag clinic assess entri week endoscopi week Sc suspens Rn placebo Sc placebo Rn tablet wake night patient default Rn Sc noncompli Rn Sc develop congest cardiac failur Rn Rn Sc nausea Sc constip Sc hematemesi Sc analysi patient Sc Rn heartburn acid regurgit epigastr pain dysphagia pain vs vs vs vs Sc Rn signific differ group endoscop sc- rn-treat patient chi improv sc- rn-treat patient differ statist signific chi obviou endoscop benefit patient group Sc Rn find sucralf ranitidin patient reflux esophag trial benefit agent absenc placebo control group high default rate sucralf firm conclus specif efficaci agent condit